February 2 RxAdvocate January, 2023 — Newsletter
January Stories:
- Cervical Cancer Awareness
- Alzheimer’s Treatment
- 5 Questions Facing the Pharmaceutical Industry
January is Cervical Cancer Awareness Month
Cervical cancer was once a leading cause of cancer death for women in the United States. Today, screening and prevention have greatly reduced the impact of cervical cancer which as of 2022 had ~14,100 new cases and a 5-year relative survival of 66.7%. Screening via regular PAP exams can catch the disease at the precancerous stage, leading to early interventions and treatment.
However, cervical cancer is among a number of cancers that can be caused by infections with a virus- the most common pathogen being the human papillomavirus (HPV). THE FDA has approved three vaccines (Gardasil, Gardasil-9, and Cervarix) to help protect against the virus resulting in the prevention of most cases. HPV vaccines can be given starting at 9 years of age and is generally a 2-dose series. The CDC does recommend that everyone through age 26 receive the HPV vaccine if they have not been fully vaccinated already.
Alzheimer’s Treatment Gets Green Light
Earlier this year, the FDA approved an accelerated approval for Leqembi – a drug that targets the pathophysiology of the debilitating disease.
Almost 6.5 million Americans are affected by the brain disorder that slowly destroys memory and thinking skills.
“Tripledemic” Threat Looms Over Holidays
“Tripledemic” Threat Looms Over Holidays
After two difficult Covid winters, the masks have come off and the current season of respiratory sickness already rivals some of the worst cold and flu seasons on record.
Public health officials are warning that a “tripledemic” of Covid-19, FLU, and R.S.V. would strain an already stressed healthcare system.
Contact us
Visit us on the web at www.rxconnectionllc.com.
If you would like additional information on our services please contact:
Orlando Neal — Principal
Orlando.Neal@rxconnectionllc.com
Orlando.Neal@rxconnectionllc.com